Berobenatide is one of the keys to Pfizer's future.

Pfizer will reduce its costs by $2.5 billion in another round of cutbacks, which will kick in next year and run through 2029. The New York company unveiled the plan in its second-quarter earnings ...

The drugmaker posted adjusted earnings of 77 cents per share and now expects full-year revenue of $60.5 billion to $62.5 ...

Pfizer reported better-than-expected second-quarter results on Tuesday, powered by strong demand for blood thinner Eliquis ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with ...

Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion ...

There are actually two factors to consider in the current drawdown. The first is the massive stock price spike that occurred during the coronavirus pandemic. Pfizer was one of a small number of ...

Pfizer's non-COVID-19 portfolio demonstrates resilience, with Padcev, Vyndamax, and new launches driving operational growth ...

Pfizer has a 6.8% yield at a time when the market's yield is roughly 1%: Is there something wrong?

Hatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

Aug 4 (Reuters) - Pfizer on ⁠Tuesday ⁠slightly raised ⁠the lower end of its full-year ​revenue forecast after beating Wall ...